| Claudia Nielsen, PHARMD | |
|
949 W Grassland Dr, American Fork, UT 84003-2753 | |
| (801) 472-8935 | |
| Not Available |
| Full Name | Claudia Nielsen |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 949 W Grassland Dr, American Fork, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265032684 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Claudia Nielsen, PHARMD 949 W Grassland Dr, American Fork, UT 84003-2753 Ph: (801) 472-8935 | Claudia Nielsen, PHARMD 949 W Grassland Dr, American Fork, UT 84003-2753 Ph: (801) 472-8935 |
News Archive
It turns out that the type, how frequent, and where new mutations occur in the human genome depends on which DNA building blocks are nearby, found researchers from the Perelman School of Medicine at the University of Pennsylvania in an advanced online study published this week in Nature Genetics.
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
Researchers compared the responses against several SARS-CoV-2 VoCs in sera from individuals exposed to variant infection, vaccination, or both.
ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.
› Verified 5 days ago
Ashley Tiffiny Boyes Hattingh, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 135 E Main St, American Fork, UT 84003 Phone: 801-756-2411 | |
Kurt Keisel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 949 W Grassland Dr, American Fork, UT 84003 Phone: 801-492-1106 | |
Justin Guernsey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 608 W Main St, T-1814, American Fork, UT 84003 Phone: 801-756-5997 | |
Dr. Chad Reed Johnson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 98 N 1100 E Ste 101, American Fork, UT 84003 Phone: 801-492-2599 | |
Jana B Goodell, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 608 W Main St, American Fork, UT 84003 Phone: 801-756-5997 | |
Dr. Austin Cameron Hill, PHARMD, PHD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 76 N 1100 E, American Fork, UT 84003 Phone: 801-756-4021 | |
Edmond Ray Beasley, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 76 N 1100 E, American Fork, UT 84003 Phone: 801-756-4021 |